[Donanemab in Early Symptomatic Alzheimer's Disease: Navigating Divergent Evidence Standards Between Regulatory Approval and Added-Benefit Assessment (AMNOG)].
- DOI
- 10.1055/a-2989-2517
- Published
- 2026 Nov 6
- Container
- Fortschritte der Neurologie-Psychiatrie
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1055/a-2989-2517,
title = {[Donanemab in Early Symptomatic Alzheimer's Disease: Navigating Divergent Evidence Standards Between Regulatory Approval and Added-Benefit Assessment (AMNOG)].},
author = {Zschocke J and Vöglein J and Dichter S and Heisser T and Maurer P and Doerr M and Scharf M and Opalka J and Perneczky R and A Onur O},
year = {2026},
journal = {Fortschritte der Neurologie-Psychiatrie},
doi = {10.1055/a-2989-2517},
url = {https://doi.org/10.1055/a-2989-2517}
}RIS
TY - JOUR TI - [Donanemab in Early Symptomatic Alzheimer's Disease: Navigating Divergent Evidence Standards Between Regulatory Approval and Added-Benefit Assessment (AMNOG)]. AU - Zschocke J AU - Vöglein J AU - Dichter S AU - Heisser T AU - Maurer P AU - Doerr M AU - Scharf M AU - Opalka J AU - Perneczky R AU - A Onur O PY - 2026 JO - Fortschritte der Neurologie-Psychiatrie DO - 10.1055/a-2989-2517 UR - https://doi.org/10.1055/a-2989-2517 ER -
APA
J, Z., J, V., S, D., T, H., P, M., M, D., M, S., J, O., R, P., & O, A. O. (2026). [Donanemab in Early Symptomatic Alzheimer's Disease: Navigating Divergent Evidence Standards Between Regulatory Approval and Added-Benefit Assessment (AMNOG)].. Fortschritte der Neurologie-Psychiatrie. https://doi.org/10.1055/a-2989-2517
Source records
- pubmed · retrieved 2026-11-10T08:14:53.575Z